Navigation Links
Intrinsic Bioprobes Launches Three New CLIA Approved Mass Spectrometry-Based Tests for Proteins Implicated in Kidney Disease and Renal Failure
Date:4/20/2011

TEMPE, Ariz., April 20, 2011 /PRNewswire/ -- Intrinsic Bioprobes Inc. ("IBI") today announced the launch of its first mass spectrometry-based protein assays for in-vitro diagnostic testing. The assays for beta-2-microglobulin, cystatin C, and retinol binding protein are performed on IBI's MASSAY® platform at the CLIA-certified and College of American Pathology (CAP) accredited diagnostic laboratory of the Institute of Genomics Medicine, UMDNJ-New Jersey Medical School.

"The assays are based on IBI's proprietary Mass Spectrometric Immunoassay (MSIA™) technology that in addition to quantification, provides a unique insight into the structural heterogeneity of each protein biomarker," says Dobrin Nedelkov, Ph.D., the CEO and Scientific Director of Intrinsic Bioprobes. The three target proteins - beta-2-microglobulin, cystatin C, and retinol binding protein - are FDA approved clinical markers for in-vitro diagnosis of kidney disease and renal failure. However, all three proteins exhibit structural microheterogeneity that gives rise to protein variants that are not detected by conventional tests. "With these new assays, clinical studies can be initiated to delineate the importance of structural variants in the onset and progression of disease," adds Nedelkov. "We are pleased that we can offer the quality and reproducibility of centralized testing and certify that the assays are performed to the rigorous standards established by CLIA."

"We are excited to perform these assays at our molecular diagnostics laboratory," says Peter Tolias, Ph.D., Professor and Executive Director of the Institute for Genomics Medicine ("IGM"). The Institute is dedicated to biomarker discovery and the clinical evaluation of biomarkers and operates research, development, as well as CLIA-certified CAP-accredited clinical diagnostic testing laboratories. "We have substantial access to patients through our affiliated hospitals and clinics and are interested in undertaking a clinical trial to evaluate structural heterogeneity within these three clinical markers in patients with renal dysfunction," adds Tolias.

Intrinsic Bioprobes Inc. (IBI), located in Tempe, AZ, performs unbiased discovery, verification and population studies on full-length proteins, and discovers and defines microheterogeneity in disease-associated biomarker proteins within healthy and disease populations. IBI's principal focus is the development and application of clinical and diagnostic assays and platforms for rapid and sensitive protein biomarker analysis for early detection and efficient treatment of critical human diseases. IBI's advanced technologies are patented and proprietary process platforms and approaches for proteomic and other research and clinical applications that generally leverage advanced mass spectrometry technology. These approaches include IBI's MASSAY® technology system, its Mass Spectrometric Immunoassay (MSIA™) technology and its Bioreactive Probes (BRP™). The Company has developed a deep and growing base of intellectual property in its field, consisting of 19 issued patents and numerous pending patent applications.

For more information about Intrinsic Bioprobes Inc., please visit http://www.intrinsicbio.com.

Contact:

Dobrin Nedelkov
Intrinsic Bioprobes Inc.
Tel. (480) 804-1778
E-mail: info@intrinsicbio.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Intrinsic Bioprobes Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Airo Wireless Announces the Release of the Intrinsically Safe A25is Cell Phone/PDA
2. Intrinsic Bioprobes, Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer-Related Proteins
3. ePharmaSolutions Launches New Application to Streamline Single Sign-On and User Account Provisioning for Sponsors Using Multiple Clinical Trial Technologies
4. Mylan Launches Generic Version of Sandostatin®
5. Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development
6. Finesse Launches the VirtualTransmitter Module and TruFluor Transmitter Blades for Seamless Integration of Single-Use Sensors Into Bioreactor Control
7. Intrasphere Technologies Launches SafetyXpress(TM) for Oracle(R) Argus Safety
8. Sigma® Life Science Launches Suite of Knockout Rats to Model Parkinsons Disease
9. M-3 Information, a Leader in Expert Behavioral Health Solutions, Launches M3Clinician.com
10. Sigma® Life Science Launches Pre-designed CompoZr® Knockout Zinc Finger Nucleases for Entire Human Genome
11. MO BIO Laboratories, Inc. Launches Dye Dots™ Dry Gel Loading Dye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... , ... March 22, 2017...Council for Agricultural Science and Technology, Ames, Iowa. ... innovation in smart, sustainable ways. Humans depend on plants for food, feed, fiber, and ... This paper is the first in a series that connects science and technology to ...
(Date:3/22/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced Alexey ... present at the 5th Annual Cancer BioPartnering & ... to present to and meet with thought leaders ... companies as well as institutional investors. This event ...
(Date:3/20/2017)... Diego, CA (PRWEB) , ... ... ... (EDCs) are substances that interfere with the ability of endogenous hormones to ... or inhibiting ligand binding activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, ...
(Date:3/20/2017)... (PRWEB) , ... March 20, 2017 , ... ... expensive and laborious sample preparation methods in order to reduce the impact on ... outside of the area of elemental analysis. , This presentation will discuss ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
Breaking Biology News(10 mins):